Medical-surgical teamwork cures severe insulin condition in newborns

May 27, 2003

Fort Lauderdale, Fla.-- Researchers from The Children's Hospital of Philadelphia successfully cured 91 percent of infants of a rare but serious condition called focal congenital hyperinsulinism (HI). In this condition, excess levels of insulin cause low blood sugar, which may lead to irreversible brain damage in children.

Using a team approach combining medical tests, operative biopsies and precise, technically demanding surgery, the physicians were able to cure newborns of focal congenital HI without causing diabetes, a common complication of conventional HI surgery.

N. Scott Adzick, M.D., surgeon-in-chief at The Children's Hospital of Philadelphia, described this research today at the annual meeting of the American Pediatric Surgical Association.

Dr. Adzick reported results from a study of 34 children with a median age of 7 weeks who underwent surgery from 1999 to 2002 at The Children's Hospital of Philadelphia. As determined by both preoperative testing and an operative biopsy, all the children had the focal form of congenital HI, in which the abnormal tissue is confined to a limited area of the pancreas, the organ that produces insulin.

Of the 34 patients, 31 did not subsequently require medication to control their insulin levels. The remaining three children continued to require medical treatment for low blood sugar, but like all 34 patients, did not develop diabetes.

Both HI and diabetes involve an imbalance of insulin. Hyperinsulinism results from excess insulin; diabetes from insufficient insulin. While some forms of HI in infants are transient and relatively common, congenital HI is a rare genetic disease, with several subtypes, based on specific mutations.

The most severe forms of congenital HI affect an estimated 100 to 200 infants annually in the U.S. Of that number, approximately two-thirds may have the focal type, as found by the Children's Hospital team.

The Children's Hospital team uses medical tests performed by interventional radiologists to guide the diagnosis and the delicate surgery on the infant's pancreas, an organ the size of an adult's little finger.

The surgical team performed a partial pancreatectomy, removing the diseased portion of the pancreas while leaving the rest of the organ intact. In contrast, in the other form of congenital HI, diffuse HI, abnormal tissue permeates the pancreas, and 98 percent of that organ must usually be removed. This near-total pancreatectomy leaves the child at risk for diabetes.

At most centers where surgery is performed for HI, near-total pancreatectomies are the norm, because physicians are unable to accurately differentiate between diffuse and focal HI. Children's Hospital is the only center in the United States, and one of only two in the world, to perform partial pancreatectomies for focal HI.

The physicians use interventional radiology techniques to help distinguish focal HI from diffuse HI before the surgery. These are selective stimulation and sampling of blood vessels in different parts of the pancreas to help pinpoint the location of the abnormal cells. During the surgery, they use pancreatic biopsies, analyzed rapidly by a pathologist, to confirm that diseased tissue is removed.

"We draw on the talents of a full team - pediatric endocrinologists, radiologists, pathologists and surgeons - to achieve these results," said Charles A. Stanley, M.D., chief of Endocrinology at Children's Hospital. "This team approach enables us to distinguish focal disease from diffuse disease, identify the specific site of the focal lesion and perform a surgical cure for the vast majority of children with focal hyperinsulinism."

Dr. Adzick's and Dr. Stanley's co-authors from The Children's Hospital of Philadelphia were Robin D. Kaye, M.D., chief of Interventional Radiology; and Eduardo Ruchelli, M.D., an attending pathologist. Another co-author, Paul S. Thornton, M.D., was at Children's Hospital when the study was conducted, but is now at Cook Children's Healthcare System, Fort Worth, Tex.
-end-
Founded in 1855 as the nation's first pediatric hospital, The Children's Hospital of Philadelphia is ranked today as the best pediatric hospital in the nation by a comprehensive Child magazine survey. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking second in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 381-bed hospital recognition as a leading advocate for children and adolescents from before birth through age 19. For more information, visit www.chop.edu.

Children's Hospital of Philadelphia

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.